Production (Stage)
Nektar Therapeutics
NKTR
$0.666
-$0.0088-1.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -51.66% | 22.15% | -0.08% | 14.59% | 0.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -51.66% | 22.15% | -0.08% | 14.59% | 0.21% |
| Cost of Revenue | -- | 9.53% | -64.32% | 39.26% | 20.88% |
| Gross Profit | -20.18% | 27.68% | 68.10% | 1.81% | -9.83% |
| SG&A Expenses | 20.83% | -1.07% | -10.36% | 14.78% | -4.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.26% | -1.26% | 1.34% | 9.96% | -4.30% |
| Operating Income | -28.78% | 19.50% | -2.37% | -7.17% | 6.93% |
| Income Before Tax | -37.99% | 116.63% | 19.28% | -2.24% | 73.13% |
| Income Tax Expenses | 248.57% | -793.10% | 114.75% | 197.87% | 44.44% |
| Earnings from Continuing Operations | -38.26% | 117.26% | 19.15% | -2.43% | 73.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.26% | 117.26% | 19.15% | -2.43% | 73.14% |
| EBIT | -28.78% | 19.50% | -2.37% | -7.17% | 6.93% |
| EBITDA | -33.78% | 16.06% | -4.71% | -9.87% | 5.38% |
| EPS Basic | -27.62% | 115.71% | 26.42% | 7.01% | 73.95% |
| Normalized Basic EPS | -30.41% | 14.67% | 2.56% | -2.37% | 11.67% |
| EPS Diluted | -27.62% | 115.43% | 26.42% | 7.01% | 73.95% |
| Normalized Diluted EPS | -30.41% | 16.19% | 2.56% | -2.37% | 11.67% |
| Average Basic Shares Outstanding | 8.31% | 9.79% | 9.90% | 10.11% | 3.11% |
| Average Diluted Shares Outstanding | 8.31% | 11.81% | 9.90% | 10.11% | 3.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |